Cargando…
Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020
The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877256/ https://www.ncbi.nlm.nih.gov/pubmed/35214640 http://dx.doi.org/10.3390/vaccines10020181 |
_version_ | 1784658377212690432 |
---|---|
author | Shen, Sijia Ge, Shen Zhang, Zheng Ma, Jianxin Jiao, Yang Li, Qian Liang, Yan Li, Shuming |
author_facet | Shen, Sijia Ge, Shen Zhang, Zheng Ma, Jianxin Jiao, Yang Li, Qian Liang, Yan Li, Shuming |
author_sort | Shen, Sijia |
collection | PubMed |
description | The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1), 5 (Y5) and 10 (Y10) years after the hepatitis B vaccination. The following data was collected and analyzed: antibody against hepatitis B virus surface antigen(anti-HBs) positive rates and geometric mean concentration (GMC) between the different compared groups through questionnaires and laboratory detection, including hepatitis B virus surface antigen (HBsAg), anti-HBs and antibody against hepatitis B virus core antigen(anti-HBc). All 600 subjects completed the questionnaires and serological tests. Among all subjects, the positive rates of HBsAg, anti-HBs and anti-HBc were 0, 70.5% (423/600) and 2.5% (15/600), respectively. The anti-HBs positive rates in Y1, Y5 and Y10 groups were 86.5% (173/200), 71.0% (142/200) and 54.0% (108/200) (χ(2) = 50.8, p < 0.001) and showed a linear decreasing trend year by year (trend χ(2) = 50.7, p < 0.001). The GMC in Y1, Y5 and Y10 groups were 296.6 mIU/mL, 51.6 mIU/mL and 25.5 mIU/mL (H = 64.8, p < 0.001), respectively. The anti-HBs positive rates and GMC decreased rapidly after the vaccination of adults against hepatitis B. Screening after 5–10 years and booster vaccination for the unprotected population is recommended. |
format | Online Article Text |
id | pubmed-8877256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88772562022-02-26 Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 Shen, Sijia Ge, Shen Zhang, Zheng Ma, Jianxin Jiao, Yang Li, Qian Liang, Yan Li, Shuming Vaccines (Basel) Article The persistence of immunity after hepatitis B vaccination is still under investigation in adults. In Chaoyang District, Beijing, people who were aged ≥ 18 years and completely immunized with HBV vaccine according to the standard procedure (0–1–6 months) were enrolled. Three groups were set for 1 (Y1), 5 (Y5) and 10 (Y10) years after the hepatitis B vaccination. The following data was collected and analyzed: antibody against hepatitis B virus surface antigen(anti-HBs) positive rates and geometric mean concentration (GMC) between the different compared groups through questionnaires and laboratory detection, including hepatitis B virus surface antigen (HBsAg), anti-HBs and antibody against hepatitis B virus core antigen(anti-HBc). All 600 subjects completed the questionnaires and serological tests. Among all subjects, the positive rates of HBsAg, anti-HBs and anti-HBc were 0, 70.5% (423/600) and 2.5% (15/600), respectively. The anti-HBs positive rates in Y1, Y5 and Y10 groups were 86.5% (173/200), 71.0% (142/200) and 54.0% (108/200) (χ(2) = 50.8, p < 0.001) and showed a linear decreasing trend year by year (trend χ(2) = 50.7, p < 0.001). The GMC in Y1, Y5 and Y10 groups were 296.6 mIU/mL, 51.6 mIU/mL and 25.5 mIU/mL (H = 64.8, p < 0.001), respectively. The anti-HBs positive rates and GMC decreased rapidly after the vaccination of adults against hepatitis B. Screening after 5–10 years and booster vaccination for the unprotected population is recommended. MDPI 2022-01-25 /pmc/articles/PMC8877256/ /pubmed/35214640 http://dx.doi.org/10.3390/vaccines10020181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shen, Sijia Ge, Shen Zhang, Zheng Ma, Jianxin Jiao, Yang Li, Qian Liang, Yan Li, Shuming Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title | Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title_full | Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title_fullStr | Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title_full_unstemmed | Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title_short | Persistence of Immunity in Adults after 1, 5 and 10 Years with Recombinant Hepatitis B Vaccine in Beijing in 2010–2020 |
title_sort | persistence of immunity in adults after 1, 5 and 10 years with recombinant hepatitis b vaccine in beijing in 2010–2020 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877256/ https://www.ncbi.nlm.nih.gov/pubmed/35214640 http://dx.doi.org/10.3390/vaccines10020181 |
work_keys_str_mv | AT shensijia persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT geshen persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT zhangzheng persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT majianxin persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT jiaoyang persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT liqian persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT liangyan persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 AT lishuming persistenceofimmunityinadultsafter15and10yearswithrecombinanthepatitisbvaccineinbeijingin20102020 |